论文部分内容阅读
IgE在Ⅰ型超敏反应中起决定性作用,因而IgE抗体生成的调节将成为Ⅰ型变态反应性疾病基本疗法之一。为此目的,必须研究IgE应答中各种免疫活性细胞及其所产生的各种可溶性因子的免疫学作用。Okumura和Tada第一个获得直接证据证明,IgE应答需T细胞。他们发现切除胸腺新生大鼠对DNP-载体免疫不产生IgE抗体;补充正常的或载体免疫的胸腺细胞,则此缺陷得以重建。Tada及其同事用大鼠模型,Katz实验室及Ovary等在小鼠中均证明,一些理化措施能干扰、改变IgE抗体应答形式。这些处置手段包括:(1)低或中等剂量全身
IgE plays a decisive role in type I hypersensitivity, and thus the regulation of IgE antibody production will be one of the basic therapies for type I allergic disease. To this end, it is necessary to study the immunological effects of various immunocompetent cells in IgE responses and the various soluble factors they produce. Okumura and Tada have the first direct evidence that IgE responses require T cells. They found that excision of thymus neonatal rats did not produce IgE antibodies to DNP-vector immunity; this defect was reconstituted with normal or vehicle-immunized thymocytes. Tada and colleagues in the rat model, Katz Laboratory and Ovary in mice have shown that some physical and chemical measures can interfere with, change the IgE antibody response form. These treatments include: (1) Low or medium dose systemic